Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04050462
Title A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NYU Langone Health

hepatocellular carcinoma


BMS-986253 + Nivolumab


Cabiralizumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.